LM-302 + S-1 + paclitaxel

LM-302 + S-1 + paclitaxel is a combination therapy regimen being evaluated for the treatment of Claudin 18.2-positive gastric and gastroesophageal junction cancers. The regimen consists of **LM-302**, an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2) conjugated to a cytotoxic payload (typically monomethyl auristatin E); **S-1**, an oral fluoropyrimidine combination drug containing tegafur (a 5-FU prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (an orotate phosphoribosyltransferase inhibitor); and **paclitaxel**, a taxane that stabilizes microtubules to inhibit cell division. This specific combination is being investigated in the Phase 2 DRAGON-12 trial, particularly for patients with peritoneal metastasis, where paclitaxel is administered both intravenously and intraperitoneally to maximize local and systemic efficacy.

Other names

LM-302 plus S-1 plus paclitaxelLM302 plus S-1 plus paclitaxelLM 302 plus S-1 plus paclitaxelLM-302 and S-1 plus intraperitoneal paclitaxelLM302 and S-1 plus intraperitoneal paclitaxelLM 302 and S-1 plus intraperitoneal paclitaxel